News

April 21, 2010 – More than 100,000 amputations are performed each year in the United States on patients with critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD...

April 5, 2010 – Patient enrollment was recently completed in the Small Vessel and Long Lesion trials of the PLATINUM clinical program. It is designed to compare the platinum chromium Promus...

March 26, 2010 – Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-elevated myocardial infarction (STEMI) undergo multivessel primary percutaneous coronary...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

March 15, 2010 — Results from the PERSEUS clinical program demonstrate positive safety and efficacy outcomes in workhorse lesions for a new platinum chromium stent system.

March 15, 2010 — Investigators reported the long-term follow-up of the largest randomized comparison between the two drug-eluting stents during the American College of Cardiology annual meeting...

March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed continued positive clinical results for the Xience V everolimus-eluting coronary stent...

March 8, 2010 – A self-expanding and disconnectable stent today gained CE mark approval in Europe to treat acute coronary syndrome (ACS).

March 8, 2010 – Six-month follow-up data on the Stentys drug-eluting and bare metal stents showed a 4 percent restenosis rate in complex lesions.

March 5, 2010 – Experts will lead an evening symposium during ACC 2010 that will cover the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease....

February 11, 2010 – Former president Bill Clinton received two coronary stents today after being admitted to the hospital with chest pain.

February 2, 2010 – Data published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrate good safety and efficacy, low target vessel revascularization (TVR) and no late stent...

February 1, 2010 – Three patent disputes between Boston Scientific Corp. and Johnson & Johnson (J&J) were settled today with Boston paying $1.7 billion.

The disputes date back to...

January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in patients with bifurcation lesions and those with non-ST-segment elevation acute coronary...

January 8, 2010 – Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent. Abbott said it plans to launch sales in Japan in the coming weeks, immediately...

January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.

January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet...

November 17, 2009 – Following positive three-year data from the first 30 patients treated with a fully bioabsorbable drug-eluting coronary stent, Abbott is initiating a large-scale trial with...

November 10, 2009 – Clinically, stent fracture has been reported in 1-2 percent of patients after drug-eluting stent (DES) implantation, but researchers at the CVPath Institute Gaithersburg, Md....

November 3, 2009 – Boston Scientific Corp. yesterday said it received CE Mark for its PROMUS Element Everolimus-Eluting Coronary Stent System.

November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the XIENCE V Everolimus-Eluting Coronary Stent System have received additional new CE...

October 21, 2009 – Raydiance Corp., developer of the world’s first commercial-grade ultrafast laser, said today it made a major breakthrough in manufacturing a wide variety of bioabsorbable...

October 14, 2009 – Medtronic Inc. yesterday initiated a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent (DES)...

October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial...

October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberté...

October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting Stent with a bioabsorbable polymer was highlighted by the company at TCT 2009.

September 30, 2009 – New clinical data released at TCT 2009 last week showed strong and sustained efficacy and safety of the Resolute Zotarolimus-Eluting Coronary Stent from Medtronic Inc. in long...

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...

September 29, 2009 – Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve several pending lawsuits over intellectual property related to drug-eluting stent...

September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus and myolimus-eluting coronary stent systems...

September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety and efficacy of the TAXUS Express2...

September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving the TAXUS Liberte stent, and patients...

September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio...

September 21, 2009 — Anticipating a change in the practice of interventional cardiology, Medtronic Inc.

September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER Sirolimus-Eluting Coronary Stent – the 2.25 mm...

September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its PLATINUM clinical program, a global, randomized, pivotal controlled trial designed...

September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco,...

September 17, 2009 – Boston Scientific Corp. announced its schedule of the company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 21st annual...

September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be featured in multiple sessions at the 21st annual Transcatheter Cardiovascular...

Sept. 14, 2009 – Abbott said today the Chinese State Food and Drug Administration (SFDA) has approved the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery...

Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...

September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).

September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System...

September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take...

August 13, 2009 – Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed to evaluate the safety and effectiveness of the company's XIENCE V Everolimus-...

August 11, 2009 – Physicians in the United Kingdom yesterday completed patient implants using the first CE mark approved drug-eluting stent designed specifically to treat severe peripheral artery...

July 16, 2009 – Boston Scientific Corp. today said its received approval from the FDA to market its TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System designed for long lesions.

July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for target vessel revascularization (TVR), these stents appear to be associated with...

July 10, 2009 – Drug-eluting stent developer Xtent Inc. is hoping to sell off its assets in August and is in on-going negotiations with two potential buyers.

June 23, 2009 – Abbott said today it received CE mark (Conformite Europeenne) for its next-generation Xience PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery...

June 18, 2009 – Abbott this week initiated SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation Xience PRIME Everolimus-Eluting Coronary Stent System, currently...

June 8, 2009 - The Bypass Angioplasty Revascularization Investigation With Diabetes Trial (BARI-2D) is a useful and focused trial that builds on the body of scientific knowledge physicians use to...

June 1, 2009 - Devax Inc. today said FDA has conditionally approved an investigational device exemption (IDE) for its AXXESS Biolimus A9-Eluting Bifurcation Stent System, allowing the company to...

May 28, 2009 - Boston Scientific Corp. said yesterday it received FDA clearance to market its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES...

May 26, 2009 – AMG International GmbH last week submitted its second-generation drug-eluting stent (DES), Itrix, for regulatory review in Europe. The stent offers a bioabsorbable polymer that...

May 21, 2009 - Boston Scientific Corp. this week announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial.

May 22, 2009 - New data presented yesterday at EuroPCR from an international, post-approval, single-arm study show that Abbott's XIENCE V Everolimus Eluting Coronary Stent System demonstrated low...

May 8, 2009 - Preliminary data presented yesterday at the 32nd annual SCAI Scientific Sessions show that 82 percent of patients treated with Cook Medical’s Zilver PTX drug-eluting peripheral stent...

April 20, 2009 - Boston Scientific recently disclosed the Court of Appeals for the Federal Circuit upheld the District Court’s decision that Johnson & Johnson’s (J&J) Bx Velocity and...

April 16, 2009 -Twelve-month data from the ZEST trial presented at ACC 2009 showed the Endeavor Drug-Eluting Stent (DES) from Medtronic Inc. was associated with a statistically significant 29...

April 10, 2009 - The results of the ZEST randomized controlled trial released at ACC 2009 showed the Cypher Sirolimus-eluting Coronary Stent significantly outperformed the Endeavor and Taxus...

April 3, 2009 - Long-term data presented at ACC.09 from Abbott’s SPIRIT II clinical trial demonstrated the clinical advantages of the XIENCE V Everolimus-Eluting Coronary Stent continued to...

March 30, 2009 - An AHRQ-funded study finds a lower risk of death and heart attack in heart disease patients 65 and older who were treated with drug-coated stents to prevent blockages as compared...

March 16, 2009 - Cordis Corp. said today it plans to launch a global, head-to-head, randomized clinical trial called NEVO II, which will compare the NEVO sirolimus-eluting coronary stent to the...

March 12, 2009 - CeloNova BioSciences Inc. said yesterday physicians performing a live stent implantation during the annual scientific meeting of the Sociedad Venezolana de Cardiologia...

March 5, 2009 - In the first six-year follow-up of a pivotal study of any drug-eluting stent, the clinical benefits of the CYPHER Sirolimus-eluting Coronary Stent compared to a bare-metal stent (...

March 3, 2009 - Boston Scientific Corp. today said it launched its TAXUS Liberté Paclitaxel-Eluting Coronary Stent System in Japan.

The product was approved on Jan. 28 by the Ministry of...

February 19, 2009 - The New England Journal of Medicine this week published the results from the SYNTAX trial, in which percutaneous coronary intervention (PCI) using the TAXUS Express2 Paclitaxel...

February 16 - The CYPHER SELECT Plus Sirolimus-eluting Coronary Stent has received CE marking within the European Union (EU) for treatment of patients with diabetes, a complex and often difficult-...

February 9, 2009 - Implantation of drug-eluting stents to treat degenerative in aortocoronary saphenous vein graft (SVG) lesions is safe, according to a study published in the Jan. 15 issue of the...

February 6, 2009 - Boston Scientific Corp. yesterday submitted to the FDA the final modules of the company’s pre-market approval (PMA) applications for both its TAXUS Liberte Atom Paclitaxel-...

February 6, 2009 - Premier Purchasing Partners yesterday announced new agreements for drug-eluting coronary stents with Abbott Laboratories Inc., Abbott Vascular and Cordis Corp.

The 13-...

February 3, 2009 – Medtronic has completed enrollment in PROTECT, the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher DES.

February 2, 2009 - Boston Scientific Corp. today said it began patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the company’s PROMUS Element Everolimus-Eluting...

January 29, 2009 - Boston Scientific Corp. said today it received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS Liberte Paclitaxel-Eluting Coronary...